TYAN
2.6.2021 17:02:07 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, brings a variety of AI, cloud and storage server platforms incorporating the latest AMD EPYC™ 7003 Series processors in TYAN’s 2021 Server Solutions Online Exhibition beginning June 2nd .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005045/en/
“As the continued growth of using clouds for running HPC workloads, modern data center operators need to raise the bar for improved business outcomes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “With leadership performance and modern security features, TYAN’s 3rd Generation AMD EPYC processor-based platforms empower our customers to drive performance at a competitive price.”
Transport HX products deliver leadership compute in supercomputing and deep learning
Attendees will experience demonstrations on the latest AMD products and technologies in HPC, cloud, storage, and 5G halls at the 3D virtual environment. Leveraging 3rd Generation AMD EPYC processors, the Transport HX TN83-B8251 is a 2U dual-socket server with 16 DDR4-3200 DIMM slots, two half-height, half-length PCIe 4.0 x16 expansion slots for high-speed networking cards, and eight 3.5-inch SATA/NVMe U.2 hot-swap, tool-less drive bays. The platform supports up to four double-width GPU cards that can be easily scaled out to improve HPC and deep learning performance.
The Transport HX TS75A-B8252 is a 2U dual-socket server platform optimized for virtualization applications with support for 32 DDR4-3200/2933 DIMM slots and up to nine PCIe 4.0 x8 slots. The TS75A-B8252 accommodates 26 2.5-inch SATA hot-swap, tool-less drive bays with up to eight NVMe U.2 support by configuration. The Transport HX FT65T-B8030 is a 4U convertible tower server platform designed for cost-effective HPC applications. The system supports a single AMD EPYC 7003 Series processor, eight DDR4-3200 DIMM slots, eight 3.5-inch SATA, and two NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B8030 supports four double-width PCIe 4.0 x16 slots for GPUs to accelerate HPC applications.
Transport CX lineup is designed for cloud and data analytics requiring large memory capacity
The Transport CX GC79-B8252 and Transport CX GC79A-B8252 are 1U dual-socket server platforms that are ideal for high-density data center deployment for a variety of memory-based computing applications. Both systems feature 32 DDR4-3200/2933 DIMM slots, two standard PCIe 4.0 x16 expansion slots, and an OCP 3.0 LAN mezzanine slot. The GC79-B8252 platform provides four 3.5-inch SATA and four 2.5-inch NVMe U.2 hot-swap, tool-less drive bays, while the GC79A-B8252 platform offers twelve 2.5-inch drive bays with up to twelve NVMe U.2 support.
The Transport CX GC68-B8036-LE and Transport CX GC68A-B8036 are cost-optimized single-socket cache server platforms featuring 16 DDR4-3200/2933 DIMMs, a pair of PCIe 4.0 x16 expansion slots and an OCP 2.0 LAN mezzanine slot in a 1U chassis. The GC68-B8036-LE accommodates four 3.5-inch SATA hot-swap, tool-less drive bays for large storage capacity and four 2.5-inch hot-swap, tool-less NVMe U.2 bays for application cache usage; the GC68A-B8036 offers twelve 2.5-inch hot-swap, tool-less drive bays with support for up to twelve NVMe U.2 devices for applications for high storage performance requirements.
The Transport CX TN73-B8037-X4S is a 2U multi-node server platform with four front-serviced compute nodes. Each node supports one AMD EPYC 7003 Series processor, four 2.5-inch hot-swap, tool-less NVMe/SATA drive bays, eight DDR4-3200 DIMM slots, three internal cooling fans, two standard PCIe 4.0 x16 expansion slots, two internal NVMe M.2 slots and one OCP 2.0 LAN mezzanine slot. The platform is suited for high-density data center deployments and targets scale-out applications with large numbers of nodes.
Transport SX lineup to deliver massive I/O and memory bandwidth for storage applications
The Transport SX TS65-B8253 is a 2U dual-socket hybrid software storage server for various datacenter and enterprise deployments supporting 16 DDR4-3200 DIMM slots and seven standard PCIe 4.0 slots. The platform offers twelve front 3.5-inch hot-swap, tool-less SATA drive bays with support for up to four U.2 NVMe SSDs, and two rear 2.5-inch hot-swap, tool-less SATA drive bays for boot drive deployment.
TYAN’s Transport SX TS65-S8036 and Transport SX TS65A-S8036 are 2U single-socket storage servers with support for 16 DDR4-3200/2933 DIMM slots, five PCIe 4.0 and one OCP 2.0 LAN mezzanine slots. The TS65-S8036 accommodates twelve front 3.5-inch and two rear 2.5-inch hot-swap, tool-less SATA drive bays for cloud storage applications, up to four NVMe U.2 devices are supported on the front twelve drive bays; the TS65A-S8036 offers 26 front and two rear 2.5-inch hot-swap, tool-less drive bays for high-performance data streaming applications, the 26 front drive bays can support up to 24 NVMe U.2 devices by configuration.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
